中国P站

ISSN: 2476-2024

Diagnostic Pathology: Open Access
Open Access

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Diagnos Pathol Open, Vol 11(3)

Fleischner Society-Guided Follow-up of Incidentally Detected Pulmonary Lesions During the COVID-19 Pandemic Enables Early Lung Cancer Detection While Avoiding Unnecessary Pulmonary Resection

Leyla Nesrin Acar1*, Pınar Bıçakçıoğlu1, Seray Hazer1, Nesrin Gürçay2 and Selim Şakir Erkmen Gülhan1
1Department of Thoracic Surgery, Health and Science University, Ankara Atat眉rk Sanatoryum Training and Research Hospital, Ke莽i枚ren, Ankara, Turkey
2Department of Medical Pathology, Health and Science University, Ankara Atat眉rk Sanatoryum Training and Research Hospital, Department of Surgical Medical sciences, Clinical Cytology (Medicine), Ke莽i枚ren, Ankara, Turkey
*Corresponding Author: Leyla Nesrin Acar, Department of Thoracic Surgery, Health and Science University, Ankara Atat眉rk Sanatoryum Training and Research Hospital, Ke莽i枚ren, Ankara, Turkey, Email: acar8106@gmail.com

Received: 28-Sep-2026 / Manuscript No. DPO-26-194785 / Editor assigned: 30-Sep-2026 / PreQC No. DPO-26-194785 / Reviewed: 14-Oct-2026 / QC No. DPO-26-194785 / Revised: 21-Oct-2026 / Manuscript No. DPO-26-194785 / Accepted Date: 28-Oct-2026 / Published Date: 28-Oct-2026

Abstract

Background: The Coronavirus Disease-19 (COVID-19) pandemic markedly increased the use of thoracic Computed Tomography (CT), leading to more incidental detection of pulmonary nodules, Ground-Glass Opacities (GGOs) and pulmonary masses. This study evaluated whether management based on the 2017 fleischner society recommendations improves patient selection for surgery while avoiding unnecessary pulmonary resection.

Methods: This retrospective single-center study included patients who underwent thoracic CT for suspected COVID-19 infection between April 2019 and April 2021. Among 259 patients with incidental pulmonary lesions, those with previous malignancy or incomplete data were excluded. Pulmonary masses underwent immediate multidisciplinary evaluation, whereas GGOs and nodules were managed according to the Fleischner Society recommendations. Persistent or suspicious lesions underwent pulmonary resection. Clinical characteristics, predictors of malignancy, pathology, Overall Survival (OS) and Disease-Free Survival (DFS) were analyzed.

Results: A total of 197 patients were included: 148 (75.1%) had malignant lesions and 49 (24.9%) had benign lesions. During surveillance, 43 patients avoided surgery because of spontaneous lesion regression; complete radiological resolution was confirmed in all 38 patients with available follow-up. Age ≥ 70 years (adjusted OR 5.50; p=0.010), male sex (adjusted OR 2.28; p=0.030) and ≥ 20 pack-year smoking (adjusted OR 3.49; p=0.032) independently predicted malignancy. More than 80% of malignant tumors were Stage I-II. five-year OS and DFS were 87.2% and 92.6%, respectively.

Conclusion: Fleischner society-guided surveillance reduced unnecessary pulmonary resections while facilitating early diagnosis of surgically curable lung cancer. Guideline-based follow-up combined with multidisciplinary evaluation achieved excellent long-term oncological outcomes and should remain the preferred strategy for managing incidentally detected pulmonary lesions.

Keywords: COVID-19; Pulmonary nodule; Fleischner society; Computed tomography; Lung cancer; Pulmonary resection; Overall survival; Disease-free survival.

Introduction

Despite remarkable progress in diagnosis and treatment over the last two decades, lung cancer remains the leading cause of cancerrelated death worldwide [1,2]. According to the most recent global cancer statistics, lung cancer accounts for approximately 2.5 million new cases and remains responsible for nearly one in five cancer-related deaths worldwide. Patient survival is closely associated with the stage at diagnosis; therefore, identifying tumors at a surgically curable stage remains one of the principal objectives of thoracic oncology. Patients with completely resected stage I Non-Small Cell Lung Cancer (NSCLC) may achieve 5-year survival rates exceeding 80%, whereas survival remains poor in patients with advanced-stage disease [3,4]. Consequently, early detection remains the most effective strategy for reducing lung cancer-related mortality.

The introduction of Low-Dose Computed Tomography (LDCT) has fundamentally changed the strategy for early lung cancer detection. The National Lung Screening Trial (NLST) first demonstrated a 20% reduction in lung cancer-specific mortality among high-risk individuals undergoing annual LDCT screening compared with chest radiography [5]. Subsequently, the dutch-belgian nelson trial confirmed an even greater reduction in lung cancer mortality through volume-based Computed Tomography (CT) screening, providing robust evidence supporting implementation of organized screening programs [6]. These findings have formed the basis of current recommendations issued by the National Comprehensive Cancer Network (NCCN), United States Preventive Services Task Force (USPSTF), American College of Chest Physicians (CHEST) and European Respiratory Society (ERS) [7-10]. Furthermore, the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) recommend that incidentally detected pulmonary nodules should undergo systematic risk assessment based on clinical characteristics, smoking history, previous malignancy, family history, radiological features and multidisciplinary evaluation before definitive management is considered, highlighting the importance of standardized follow-up algorithms in daily clinical practice.

Although implementation of low-dose CT screening has significantly improved early lung cancer detection, most pulmonary nodules encountered in routine clinical practice are still detected incidentally during CT examinations performed for unrelated indications. Consequently, clinicians frequently face the challenge of distinguishing transient inflammatory abnormalities from early-stage lung cancer while avoiding unnecessary invasive procedures. Nevertheless, most pulmonary nodules encountered in routine clinical practice are detected incidentally rather than through organized screening programs. The increasing use of thoracic CT for a variety of clinical indications has resulted in a growing number of patients referred for evaluation of indeterminate pulmonary lesions. Appropriate management of these lesions has become increasingly important because unnecessary invasive procedures should be avoided without delaying diagnosis of potentially curable lung cancer [11,12]. Although the majority of these lesions are benign, distinguishing inflammatory abnormalities from early lung cancer remains one of the most challenging issues in thoracic practice.

To address this challenge, the fleischner society published updated recommendations in 2017 for the management of incidentally detected pulmonary nodules [13]. These recommendations have become an integral part of routine clinical practice by providing practical guidance regarding surveillance intervals and indications for further diagnostic evaluation according to nodule characteristics and patient-related risk factors as shown in Table 1.

During the COVID-19 pandemic, thoracic CT was frequently performed for evaluation of suspected SARS-CoV-2 pneumonia. An unintended consequence of this practice was the detection of a large number of incidental pulmonary nodules, ground-glass opacities and pulmonary masses that otherwise might have remained undiagnosed [14,15]. This unprecedented increase in incidental pulmonary lesion detection provided a unique opportunity to determine whether adherence to the fleischner society recommendations could optimize patient selection for pulmonary resection, avoid unnecessary surgery for regressive inflammatory lesions, and facilitate earlier diagnosis of surgically curable lung cancer with favorable long-term outcomes. Interpretation of these lesions was further complicated by persistent inflammatory abnormalities observed after COVID-19 infection. Organizing pneumonia, ischemic necrosis, post-inflammatory fibrosis and residual inflammatory nodules frequently mimicked earlystage lung cancer on CT imaging, making clinical decision-making considerably more challenging [16-18]. Therefore, differentiating inflammatory lesions from malignant pulmonary nodules became increasingly difficult, emphasizing the importance of structured radiological surveillance rather than immediate surgical intervention.

Although several studies have described incidental pulmonary findings during the COVID-19 era, very limited evidence exists regarding the long-term oncological outcomes of patients managed according to the fleischner society recommendations after incidental lesion detection. Furthermore, few studies have evaluated whether guideline-based surveillance successfully reduces unnecessary pulmonary resections while simultaneously improving early diagnosis of surgically curable lung cancer.

We hypothesized that implementing the fleischner society's recommendations would optimize patient selection for surgery by preventing unnecessary lung resections, improving early diagnosis of malignant lesions, and enhancing long-term oncological outcomes.

Materials and Methods

Study design and ethical approval

This is a retrospective, single-center observational study. The study protocol was reviewed and approved by the clinical research ethics committee of university of health sciences ankara keçiören training and research hospital (Approval No: 2012-KAEK-15/2250; March 9, 2021). Because of the retrospective study design, the Ethics Committee waived the requirement for written informed consent. The study complied with the ethical principles of the declaration of helsinki.

Patient selection

Patients who underwent thoracic CT between April 1, 2019 and April 1, 2021 because of suspected COVID-19 infection were retrospectively reviewed. Thoracic CT examinations demonstrating incidental pulmonary GGOs, pulmonary nodules or pulmonary masses were included. Overall, 259 patients fulfilled the initial radiological inclusion criteria. Seven patients with a previous history of malignancy and twelve patients with incomplete clinical records were excluded. Patients presenting with pulmonary masses (n=61) underwent immediate multidisciplinary evaluation by the thoracic oncology board because of a high radiological suspicion of malignancy. Patients presenting with pulmonary nodules or GGOs (n=179) entered a structured surveillance program according to the 2017 fleischner society recommendations. During surveillance, 43 lesions demonstrated complete regression or substantial radiological improvement and therefore did not require surgery. Persistent lesions, enlarging nodules or lesions with radiological features suspicious for malignancy underwent pulmonary resection (n=136). Overall, 197 patients with definitive postoperative histopathological diagnoses constituted the final study cohort. They were divided into two groups, malignant and benign, according to the pathology results (Figure 1) (Table 2).

CT finding Low-risk patient High-risk patient Recommendation
Single solid nodule <6 mm No routine follow-up Optional CT at 12 months No further imaging if stable
Single solid nodule 6-8 mm CT at 6-12 months; consider CT at 18-24 months CT at 6-12 months and again at 18-24 months Continue surveillance if stable
Single solid nodule >8 mm CT at 3 months, PET/CT and/or tissue sampling CT at 3 months, PET/CT and/or tissue sampling Multidisciplinary evaluation recommended
Multiple solid nodules <6 mm No routine follow-up Optional CT at 12 months Individualize according to dominant nodule
Multiple solid nodules ≥ 6 mm CT at 3-6 months; consider CT at 18-24 months CT at 3-6 months and at 18-24 months Management based on the most suspicious nodule
Pure ground-glass nodule <6 mm No routine follow-up No routine follow-up Usually benign
Pure ground-glass nodule ≥ 6 mm CT at 6-12 months, then every 2 years until 5 years Same recommendation Surgical evaluation if enlargement or increasing solid component
Part-solid nodule ≥ 6 mm CT at 3-6 months; if persistent, annual CT for 5 years Same recommendation Consider resection if solid component ≥ 6 mm or progressive
Multiple subsolid nodules CT at 3-6 months CT at 3-6 months Further management according to the dominant lesion

Note: CT: Computed Tomography; PET: Positron Emission Tomography. CT at 3-6 months CT at 3-6 months CT at 3-6 months.

Table 1: Fleischner society recommendations for the management of incidentally detected pulmonary nodules (2017).

diagnostic

Figure 1: Patient selection flow diagram, fleischner society-guided surveillance, surgical management, and final histopathological classification. MDT: Multidisciplinary Thoracic Oncology Team; GGO: Ground-Glass Opacity.

Clinical variables

Demographic characteristics, clinical risk factors, radiological findings, surgical data, histopathological diagnoses, and follow-up outcomes were retrieved from the hospital electronic medical records. The variables collected for analysis included age, sex, smoking status (never smoker, former smoker, and current or smoker with a cumulative smoking exposure of ≥ 20 pack-years), passive smoking exposure, family history of cancer, biomass exposure, Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD), type of pulmonary resection, final histopathological diagnosis, pathological tumor stage, Overall Survival (OS), and Disease-Free Survival (DFS). These variables were selected to evaluate factors associated with malignant histopathology and to determine the effectiveness of fleischner society-guided surveillance in achieving early diagnosis of surgically curable lung cancer and favorable long-term outcomes.

Surgical management

Undiagnosed lung lesions were treated with wedge resection and frozen section analysis. Lesions reported as benign based on intraoperative frozen section evaluation were terminated with wedge resection. Lesions reported as malignant underwent surgical resection (segmentectomy, lobectomy, bilobectomy, pneumonectomy) and lymph node dissection according to lung reserve and oncological principles. Mass lesions were evaluated by a multidisciplinary thoracic oncology board and surgical resection (segmentectomy, lobectomy, bilobectomy, pneumonectomy) and lymph node dissection were performed according to lung reserve and oncological principles.

Study outcomes

The primary endpoint was identification of clinical predictors associated with malignant histopathology. Secondary endpoints included: effectiveness of fleischner society-guided surveillance, avoidance of unnecessary surgery, distribution of surgical procedures, five-year overall survival, five-year disease-free survival.

Statistical analysis

Continuous variables were expressed as mean ± standard deviation or median (interquartile range). Categorical variables were summarized as frequencies and percentages. Comparisons between benign and malignant groups were performed using Pearson's chi-square or fisher's exact test where appropriate. Independent predictors of malignancy were evaluated using multivariable logistic regression analysis. Model calibration was assessed using the hosmer-lemeshow goodness-of-fit test. Overall survival and disease-free survival were estimated using the kaplan-meier method. A two-sided p value <0.05 was considered statistically significant.

Results

Regression during fleischner society-guided surveillance

Among the 179 patients with incidentally detected pulmonary Ground-Glass Opacities (GGOs) or nodules who entered structured surveillance according to the 2017 fleischner society recommendations, 43 (24.0%) demonstrated spontaneous radiological regression and therefore did not require pulmonary resection. Follow-up data were available for 38 of these patients, who were monitored for a median of 8 months (range, 3-14 months). Complete radiological resolution was observed in all followed patients, and none subsequently required surgical intervention. These findings indicate that guideline-based surveillance safely prevented unnecessary pulmonary resection in patients with transient inflammatory pulmonary lesions.

Baseline clinical characteristics

The mean age of the total cohort was 59.7 ± 11.3 years. Patients with malignant lesions were older than those with benign pathology (62.3 ± 9.8 vs. 52.1 ± 12.4 years, p<0.001). Male sex was more frequent in the malignant group than in the benign group (75.0% vs. 51.0%, p=0.003). Smoking exposure was also more frequent among patients with malignant lesions. In particular, ≥ 20 pack-year smoking exposure was observed in 96 malignant patients (64.9%) compared with 24 benign patients (49.0%) (Table 3).

Variable Total (n=197) Benign (n=49) Malignant (n=148) p value
Clinical characteristics
Age, years (mean ± SD) 59.7 ± 11.3 52.1 ± 12.4 62.3 ± 9.8 <0.001
Age ≥ 70 years 44 (22.3%) 3 (6.1%) 41 (27.7%) 0.001
Male sex 136 (69.0%) 25 (51.0%) 111 (75.0%) 0.003
COPD: Chronic Obstructive
Pulmonary Disease
30 (15.2%) 9 (18.4%) 21 (14.2%) 0.634
Interstitial lung disease 13 (6.6%) 5 (10.2%) 8 (5.4%) 0.4
Biomass exposure 10 (5.1%) 4 (8.2%) 6 (4.1%) 0.269
Family history of cancer 10 (5.1%) 2 (4.1%) 8 (5.4%) 1
Never smoker 17 (8.6%) 8 (16.3%) 9 (6.1%) 0.039
Former smoker 59 (29.9%) 17 (34.7%) 42 (28.4%)  
≥ 20 pack-year smoker 120 (60.9%) 24 (49.0%) 96 (64.9%)  
Radiological characteristics
Ground-glass opacity 59 (29.9%) 21 (42.9%) 38 (25.7%) 0.036
Pulmonary nodule 74 (37.6%) 28 (57.1%) 46 (31.1%) 0.002
Pulmonary mass 61 (31.0%) 0 (0.0%) 61 (41.2%) <0.001
Surgical characteristics
Right-sided resection 121 (61.4%) 37 (75.5%) 84 (56.8%) 0.03
Left-sided resection 76 (38.6%) 12 (24.5%) 64 (43.2%)  
Wedge resection 43 (21.8%) 43 (87.8%) 0 (0.0%) <0.001
Segmentectomy 21 (10.7%) 0 (0.0%) 21 (14.2%)  
Lobectomy 102 (51.8%) 0 (0.0%) 102 (68.9%)  
Bilobectomy 6 (3.0%) 0 (0.0%) 6 (4.1%)  
Pneumonectomy 19 (9.6%) 0 (0.0%) 19 (12.8%)  
Other limited resection 6 (3.0%) 6 (12.2%) 0 (0.0%)  

Table 3: Baseline clinical, radiological and surgical characteristics of the study cohort.

Radiological findings and surgical management

Radiological presentation differed significantly between benign and malignant groups. Pulmonary masses were observed exclusively in patients with malignant pathology, whereas nodules and groundglass opacities were more frequently represented among patients with benign or indeterminate lesions selected for surveillance. Surgical management also differed markedly between groups. Wedge resection was the predominant procedure for benign lesions, while lobectomy represented the most common procedure in malignant lesions (Table 3). Invasive adenocarcinoma was the most common malignant histology, followed by squamous cell carcinoma (Table 4).

Histopathological diagnosis Benign (n=49) Malignant (n=148) Total (n=197)
Malignant lesions
Invasive adenocarcinoma 0 79 (53.4%) 79 (40.1%)
Squamous cell carcinoma 0 62 (41.9%) 62 (31.5%)
Adenocarcinoma in situ 0 3 (2.0%) 3 (1.5%)
Large-cell carcinoma 0 4 (2.7%) 4 (2.0%)
Benign lesions
Ischemic necrosis 27 (55.1%) 0 27 (13.7%)
Organizing pneumonia 13 (26.5%) 0 13 (6.6%)
Hamartoma 9 (18.4%) 0 9 (4.6%)

Table 4: Histopathological diagnosis according to final pathology.

Histopathological findings

Among malignant lesions, invasive adenocarcinoma represented the most frequent histological subtype, followed by squamous cell carcinoma. Adenocarcinoma in situ and large-cell carcinoma accounted for only a small proportion of malignant tumors.

Among benign lesions, ischemic necrosis and organizing pneumonia predominated, together accounting for more than 80% of all benign pathological diagnoses. Hamartoma represented the remaining benign lesions. This pathological distribution reflects the unique inflammatory consequences of the COVID-19 pandemic and emphasizes the diagnostic challenges posed by persistent postinflammatory pulmonary abnormalities (Table 4).

Independent predictors of malignancy

Multivariable logistic regression identified age ≥ 70 years (adjusted or 5.50; 95% CI 1.51-20.10; p=0.010), male sex (adjusted or 2.28; 95% CI 1.08-4.80; p=0.030) and heavy smoking (≥ 20 pack-years; adjusted or 3.49; 95% CI 1.11-10.89; p=0.032) as independent predictors of malignant histopathology.

Former smoking demonstrated a positive but statistically nonsignificant association with malignancy. Similarly, COPD, interstitial lung disease, biomass exposure, and family history of cancer were not independently associated with malignant pathology after multivariable adjustment (Table 5 and Figure 2).

Variable Adjusted OR 95% CI p value
Age ≥ 70 years   1.51-20.10 0.01
Male sex 2.28 1.08-4.80 0.03
Former smoker 2.15 0.65-7.12 0.209
≥ 20 pack-year smoker 3.49 1.11-10.89 0.032
COPD 0.45 0.17-1.19 0.108
ILD 0.52 0.15-1.84 0.313
Biomass exposure 1.08 0.26-4.51 0.918
Family history of cancer 1.43 0.27-7.46 0.673

Note: CI: Confidence Interval; COPD: Chronic Obstructive Pulmonary Disease; ILD: Interstitial Lung Disease; OR: Odds Ratio. Reference categories: Age <70 years, female sex, never smoker and absence of the listed comorbidity/exposure.

Table 5: Multivariable logistic regression for predictors of malignancy.

pathology

Figure 2: Forest plot of the multivariable logistic regression (Log Scale), Forest plot showing adjusted odds ratios (ORs) and 95% confidence intervals. The x-axis is logarithmic; the dashed vertical line indicates OR=1.0.

Overall survival and disease-free survival

After surgery, 52 patients received chemotherapy and 5 patients received chemoradiotherapy. During a median follow-up of approximately 60 months, recurrence occurred in two patients (1.4%), whereas distant metastases developed in nine patients (6.1%). These were: brain metastases in 4 patients, liver metastases in 2 patients, adrenal metastases in 1 patient, bone metastases in 1 patient, and contralateral lung metastases in 1 patient. One patient developed a bronchopleural fistula, one patient died due to respiratory failure, one patient died due to myocardial infarction, and one patient died due to heart failure in the early postoperative period. Nineteen patients (9.6%) with malignant disease died during follow-up. The overall 5-year survival rate was found to be 87.2%, and the 5-year disease-free survival rate was 92.6%.

The pathological stage distribution and survival rates in 148 patients with malignant lesions are summarized in Table 6. Early-stage disease was dominant: Stage I tumors were detected in 76 patients (51.4%), Stage II disease in 44 patients (29.7%) and Stage III disease in 28 patients (18.9%). No Stage IV disease was found in the surgically treated group. The outcomes for patients with Stage I-II tumors were more favorable than those with Stage III disease. The crude mortality rate was 8 (6.7%) in Stage I-II disease and 11 (39.3%) in Stage III disease (p=0.0000). The 5-year disease-free survival rate and 5-year survival rates were higher in Stage I-II disease compared to Stage III disease, respectively (90%, 40.4% and 92%, 57.9%, p=0.0000). These findings support the observation, guided by the fleischner society, that follow-up and timely surgical resection are associated with diagnosis at a surgically treatable stage and positive long-term oncological outcomes. The predominance of Stage I-II disease indicates that structured radiological surveillance facilitated diagnosis before progression to advanced-stage disease. This finding is reflected by the excellent long-term overall and disease-free survival observed in the present cohort as shown in Figure 3.

Stage n (%) Deaths, n Crude OS (%) Mean OS, months 5-year OS (%) Mean DFS, months 5-year DFS (%)
IA1 9 (6.1) 0 100 67.2 (n=6) 100 58.1 (n=7) 100
IA2 25 (16.9) 0 100 64.5 (n=22) 100 64.5 (n=22) 100
IA3 12 (8.1) 0 100 66.0 (n=9) 100 66.0 (n=9) 100
IB 30 (20.3) 3 90 59.2 (n=23) 87 58.6 (n=23) 87
IIA 15 (10.1) 1 93.3 61.4 (n=11) 90.9 61.4 (n=11) 90.9
IIB 29 (19.6) 4 86.2 54.4 (n=18) 82.4 51.5 (n=19) 73.7
IIIA 18 (12.2) 6 66.7 42.4 (n=11) 54.5 36.9 (n=12) 50
IIIB 10 (6.8) 5 50 43.6 (n=8) 62.5 31.8 (n=10) 26.7
Stage I-II 120 (81.1) 8 (6.7) 93.3 61.0 (n=89) 92 59.6 (n=91) 90
Stage III 28 (18.9) 11 (39.3) 60.7 42.9 (n=19) 57.9 34.6 (n=22) 40.4
p value     0       0

Table 6: Association between pathological stage and survival outcomes among malignant patients.

XXXXXXX

Figure 3: Kaplan-Meier curves for overall survival and disease-free survival according to pathological stage (Stage I vs. II vs. III).

Discussion

Principal findings

The present study demonstrates that structured implementation of the 2017 fleischner society recommendations enabled early identification of surgically curable lung cancer while simultaneously preventing unnecessary pulmonary resection in patients with transient inflammatory pulmonary lesions detected during the COVID-19 pandemic [13]. Of the 179 patients with incidentally detected groundglass opacities or pulmonary nodules who entered guideline-based surveillance, 43 demonstrated spontaneous radiological regression and therefore avoided surgery. None of the 38 patients with available followup data required subsequent pulmonary resection, confirming the safety and clinical effectiveness of structured surveillance for incidental pulmonary lesions.

Our study provides three clinically important observations. First, approximately one-quarter of patients undergoing fleischner societyguided surveillance avoided pulmonary resection because their lesions regressed spontaneously during follow-up. Second, unlike prepandemic surgical series, organizing pneumonia and ischemic necrosis constituted the predominant benign pathological diagnoses, reflecting the inflammatory and vascular sequelae of SARS-CoV-2 infection [19-21]. Third, structured surveillance facilitated diagnosis of lung cancer predominantly at pathological Stage I-II, resulting in excellent five-year overall and disease-free survival. Together, these findings demonstrate that guideline-based surveillance not only improves patient selection for surgery but also enhances long-term oncological outcomes.

Comparison with previous studies

The predominance of early-stage lung cancer represents one of the most important findings of the present study. More than four-fifths of malignant tumors were diagnosed at pathological Stage I-II, and these patients demonstrated substantially better overall survival and diseasefree survival than those with Stage III disease. Early-stage surgical treatment translated into excellent long-term oncological outcomes, with a five-year overall survival of 87.2% and a five-year disease-free survival of 92.6%.

These findings are consistent with the well-established survival benefit associated with CT-based lung cancer screening programs. Both the National Lung Screening Trial (NLST) and the NEderlands–Leuvens Longkanker ScreeningsONderzoek (NELSON) trial demonstrated that low-dose CT screening substantially reduces lung cancer mortality by facilitating earlier diagnosis of surgically curable disease. Likewise, the current NCCN Guidelines continue to recommend low-dose CT screening for individuals at increased risk because early-stage detection provides the greatest opportunity for curative surgical resection.

However, relatively limited evidence exists regarding patients with incidentally detected pulmonary lesions outside organized screening programs, particularly during the COVID-19 pandemic. Our findings extend the current literature by demonstrating that structured surveillance based on the 2017 fleischner society recommendations safely reduced unnecessary pulmonary resections while maintaining excellent long-term oncological outcomes.

Furthermore, our results are consistent with the principles of the Slovak Lung Cancer Screening Initiative, which advocates standardized implementation of evidence-based screening and follow-up pathways to maximize early-stage lung cancer detection while minimizing unnecessary invasive procedures. Although our cohort consisted of patients with incidentally detected pulmonary lesions rather than participants in a formal screening program, both approaches share the common objective of identifying lung cancer at a surgically curable stage through structured radiological assessment.

COVID-19-related benign pulmonary mimickers

One of the most distinctive observations of the present study was the pathological spectrum of benign pulmonary lesions. Ischemic necrosis and organizing pneumonia accounted for the majority of benign surgical specimens. This distribution differs considerably from that reported in pre-pandemic surgical series, in which hamartoma and other benign tumors generally represent the predominant pathological diagnoses.

The increased frequency of organizing pneumonia and ischemic necrosis in our cohort is most likely related to the inflammatory and vascular sequelae of SARS-CoV-2 infection. COVID-19 is characterized by diffuse alveolar injury, endothelial dysfunction, microvascular thrombosis, and persistent inflammatory responses, all of which may produce residual pulmonary nodules or mass-like lesions that closely mimic lung cancer on CT imaging. Previous pathological studies have similarly demonstrated that organizing pneumonia, fibroinflammatory repair, and ischemic pulmonary necrosis are common late manifestations following COVID-19 pneumonia and frequently persist despite clinical recovery.

The observation that all patients with available follow-up demonstrated complete radiological resolution further supports this interpretation. Had surgery been performed immediately after the initial CT examination, many of these inflammatory lesions would have undergone unnecessary pulmonary resection. These findings emphasize the importance of short-term radiological surveillance before surgical intervention is considered in carefully selected patients [22,23].

Clinical Implications

Multivariable logistic regression identified advanced age, male sex, and heavy smoking (≥ 20 pack-years) as independent predictors of malignant pathology, findings that are consistent with previous epidemiological studies and current lung cancer screening recommendations. These results indicate that radiological surveillance should always be interpreted together with established clinical risk factors when estimating the probability of malignancy.

Our findings have direct implications for contemporary thoracic practice. Incidentally detected pulmonary nodules should not automatically prompt surgical intervention solely because of their radiological appearance. Instead, structured implementation of the fleischner society recommendations, combined with multidisciplinary evaluation and individualized clinical risk assessment, allows clinicians to distinguish transient inflammatory lesions from persistent malignant disease while minimizing unnecessary pulmonary resections.

This strategy appears particularly valuable in healthcare settings where inflammatory pulmonary abnormalities are common, such as during or after the COVID-19 pandemic. Guideline-based surveillance enables clinicians to avoid unnecessary pulmonary resections without delaying diagnosis of surgically curable lung cancer. Consequently, multidisciplinary evaluation integrating radiological findings, clinical risk factors, and interval imaging should remain the cornerstone of management of incidentally detected pulmonary lesions.

Strengths and limitations

The principal strengths of this study include the relatively large surgically confirmed cohort, complete histopathological verification of all resected lesions, comprehensive long-term oncological followup, and evaluation of incidental pulmonary lesions during the unique period of widespread thoracic CT utilization associated with the COVID-19 pandemic. These strengths provide robust evidence regarding the real-world effectiveness of guideline-based surveillance in routine thoracic surgical practice.

Nevertheless, several limitations should be acknowledged. First, this was a retrospective single-center study, which may limit the generalizability of the findings. Second, only surgically treated patients with definitive pathological diagnoses were included, introducing unavoidable selection bias. Third, pulmonary nodules that remained stable without surgical intervention were not represented in the final pathological analysis. Finally, because the study reflects clinical practice during the COVID-19 pandemic, the spectrum of benign pathological diagnoses may differ from that observed in non-pandemic populations.

Clinical perspective

The COVID-19 pandemic unexpectedly created one of the largest opportunities for incidental pulmonary lesion detection through widespread thoracic CT imaging. Our findings demonstrate that standardized implementation of the fleischner society recommendations enabled clinicians to distinguish transient inflammatory lesions from persistent malignant disease while avoiding unnecessary pulmonary resections. Importantly, structured surveillance facilitated diagnosis predominantly at surgically curable stages, resulting in excellent long-term oncological outcomes. These findings support routine implementation of the fleischner society recommendations together with multidisciplinary evaluation as the preferred management strategy for incidentally detected pulmonary lesions in contemporary thoracic practice.

Future perspectives

Future multicenter prospective studies incorporating volumetric nodule assessment, artificial intelligence-assisted CT interpretation, and radiomics-based image analysis may further improve individualized risk stratification of incidentally detected pulmonary lesions. Integration of these emerging technologies with established fleischner society-guided surveillance protocols may optimize patient selection for surgery while preserving excellent long-term oncological outcomes.

Conclusion

The present study demonstrates that strict implementation of the fleischner society recommendations safely differentiates transient inflammatory pulmonary lesions from persistent malignant disease, thereby preventing unnecessary pulmonary resections while facilitating early diagnosis of surgically curable lung cancer. Structured guidelinebased surveillance, combined with multidisciplinary evaluation and individualized risk assessment, resulted in excellent long-term oncological outcomes in this cohort. These findings support routine implementation of the fleischner society recommendations as an integral component of contemporary thoracic surgical practice for patients with incidentally detected pulmonary lesions.

Declarations

Ethics approval

The study protocol was approved by the clinical research ethics committee of the university of health sciences ankara keçiören training and research hospital (Approval No. 2012-KAEK-15/2250; March 9, 2021).

Consent to participate

The Ethics Committee waived the requirement for written informed consent because of the retrospective study design.

Funding

The authors received no financial support for this study.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgements

None.

No Heading

References

Citation: Acar LN, B脛卤çakç脛卤o脛聼lu P, Hazer S, Gürçay N,  Gülhan SSE, et al.  (2026) Fleischner Society-Guided Follow-up of Incidentally Detected Pulmonary Lesions During the COVID-19 Pandemic Enables Early Lung Cancer Detection While Avoiding Unnecessary Pulmonary Resection. Diagnos Pathol Open 11:280.

Copyright: © 2026 Acar LN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 97
  • [From(publication date): 0-0 - Nov 20, 2026]
  • Breakdown by view type
  • HTML page views: 77
  • PDF downloads: 20
International Conferences 2026-27
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top